Search results for "Platelet"

showing 10 items of 786 documents

Immediate versus delayed facilitated percutaneous coronary intervention. A pilot study

2005

The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial IschemiaEligibility DeterminationMyocardial ReperfusionPilot ProjectsAcute myocardial infarctionElectrocardiographyImmunoglobulin Fab FragmentsRestenosisInternal medicinemedicineAbciximabHumansIn patientcardiovascular diseasesThrombusAngioplasty Balloon CoronaryFacilitated pciDelayed percutaneous coronary interventionPharmacologybusiness.industryPatient SelectionPercutaneous coronary interventionAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateGIIb/IIIa inhibitorssurgical procedures operativeTreatment OutcomeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFacilitated percutaneous coronary interventionTIMIPlatelet Aggregation InhibitorsCombined therapymedicine.drug
researchProduct

Beta-Thromboglobulin and Platelet Factor 4 in Juvenile Myocardial Infarction

2006

AdultMalemedicine.medical_specialtybusiness.industryAge FactorsMyocardial InfarctionHematologyGeneral Medicine030204 cardiovascular system & hematologyPlatelet Factor 4beta-Thromboglobulinmedicine.disease03 medical and health sciences0302 clinical medicineBeta-thromboglobulinInternal medicinemedicineCardiologyHumansJuvenileFemale030212 general & internal medicineMyocardial infarctionbusinessPlatelet factor 4Clinical and Applied Thrombosis/Hemostasis
researchProduct

No evidence of platelet activation in obesity.

1993

AdultMalemedicine.medical_specialtybusiness.industryHematologyMiddle Agedmedicine.diseasePlatelet ActivationObesityEndocrinologyInternal medicinemedicineHumansFemalePlatelet activationObesitybusinessThrombosis and haemostasis
researchProduct

The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study.

2005

AbstractIn contrast with extensive documentation in patients treated with unfractionated heparin (UFH), the incidence of heparin-induced thrombocytopenia (HIT) in medical patients receiving low-molecular-weight heparin (LMWH) is less well defined. In a prospective cohort study, the platelet count was monitored in 1754 consecutive patients referred to 17 medical centers and treated with LMWH for prophylaxis or treatment of thromboembolic disorders. The diagnosis of HIT was accepted in case of a platelet drop of at least 50%, the absence of obvious explanations for thrombocytopenia, and the demonstration of heparin-dependent IgG antibodies. HIT developed in 14 patients (0.80%; 95% CI, 0.43%-1…

AdultMalemedicine.medical_specialtymedicine.drug_classImmunologyLow molecular weight heparinheparinPlatelet Factor 4BiochemistryCohort StudiesRisk FactorsHeparin-induced thrombocytopeniaInternal medicinemedicineHumansProspective StudiesProspective cohort studyAgedAged 80 and overbusiness.industryIncidence (epidemiology)IncidenceCell BiologyHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaSurgeryClinical trialTreatment OutcomeFemaleComplicationbusinessCohort studymedicine.drugBlood
researchProduct

Effects of mud-pack treatment on plasma cytokine and soluble adhesion molecule levels in healthy volunteers

2001

Abstract Background : The suggested hypothesis of a direct anti-inflammatory property of mud-pack treatment has led us to speculate that its action on the cytokine network might counteract the heat-stress-related effects on platelet and endothelial cell function often reported following hot-spring baths. Therefore, the present study was designed to investigate the effects of a cycle of 12 daily mud-pack treatments on bio-humoral markers of inflammation, as well as on markers of in vivo platelet and/or endothelial cell activation, in plasma samples obtained from healthy volunteers. Methods : Blood samples were obtained before ( T 0 ), at the end of the first treatment ( T 1 ) and after a cyc…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentClinical BiochemistryHematocritBiochemistrymud-pack treatmentBlood cellLeukocyte CountIn vivoReference ValuesInternal medicinemedicineHumansPlateletadhesion moleculesmedicine.diagnostic_testCell adhesion moleculeChemistryInterleukin-6Platelet CountTumor Necrosis Factor-alphaMud TherapyBiochemistry (medical)General MedicineHyperthermia InducedMiddle AgedPlatelet ActivationcytokinesEndothelial stem cellP-Selectinmedicine.anatomical_structureEndocrinologyCytokineHematocritHemostasisImmunologyadhesion molecules; cytokines; mud-pack treatmentFemaleEndothelium VascularE-SelectinCell Adhesion MoleculesBiomarkersInterleukin-1
researchProduct

Comparison of intermittent- and continuous-flow cell separators for the collection of autologous peripheral blood progenitor cells in patients with h…

2001

BACKGROUND: The transplantation of autologous peripheral blood progenitor cells (PBPCs) after high-dose chemotherapy is a valuable therapy for patients with hematologic and solid malignancies. Several methods are used for harvesting PBPCs. The efficiency of intermittent- and continuous-flow blood cell separators in collecting progenitor cells from the blood of patients undergoing myeloablative treatment for cancer was compared. STUDY DESIGN AND METHODS: PBPC components (n = 133) were obtained from 72 patients by leukapheresis with continuous-flow machines (Spectra, COBE; CS 3000 Plus, Baxter) and with an intermittent-flow machine (MCS 3P, Haemonetics). The data were analyzed retrospectively…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologyUrologyCD34Blood volumeAntigens CD34Cell SeparationTransplantation AutologousBlood cellmedicineImmunology and AllergyHumansPlateletLeukapheresisProgenitor cellRetrospective StudiesChemotherapybusiness.industryHematopoietic Stem Cell TransplantationHematologyLeukapheresisMiddle AgedHematopoietic Stem CellsSurgeryBlood Cell CountTransplantationmedicine.anatomical_structureHematologic NeoplasmsFemalebusinessTransfusion
researchProduct

Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with…

2018

Summary Venous thromboembolism (VTE)‐BLEED, a decision tool for predicting major bleeding during chronic anticoagulation for VTE has not yet been validated in practice‐based conditions. We calculated the prognostic indices of VTE‐BLEED for major bleeding after day 30 and day 90, as well as for recurrent VTE and all‐cause mortality, in 4457 patients enrolled in the international, prospective XALIA study. The median at‐risk time was 190 days (interquartile range 106–360). The crude hazard ratio (HR) for major bleeding after day 30 was 2·6 [95% confidence interval (CI) 1·3–5·2] and the treatment‐adjusted HR was 2·3 (95% CI 1·1–4·5) for VTE‐BLEED high (versus low) risk patients: the correspondi…

AdultMalemedicine.medical_specialtyvenous thromboembolismHemorrhage030204 cardiovascular system & hematologyDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineInterquartile rangePredictive Value of TestsInternal medicinemedicineanticoagulation therapy; bleeding; prediction; rivaroxaban; venous thromboembolism; HematologyHumans030212 general & internal medicinecardiovascular diseasesProspective StudiesAdverse effectrivaroxabanRivaroxabananticoagulation therapybusiness.industryIncidence (epidemiology)Platelets Haemostasis and ThrombosisHazard ratioHematologypredictionBleedMiddle Agedequipment and suppliesbleedingConfidence intervalddc:Survival RateCohortFemalebusinessmedicine.drugResearch Paper
researchProduct

Role of Erythropoietin in Cerebral Glioma: An Innovative Target in Neuro-Oncology

2019

Background: Erythropoietin (EPO) is a cytokine primarily involved in the regulation of erythropoiesis. In response to hypoxia–ischemia, hypoxia-inducible factor 1 induces EPO production, which, in turn, inhibits apoptosis of erythroid progenitor cells. By the same mechanism and acting through other signaling pathways, EPO exerts neuroprotective effects. Increased resistance to hypoxia and decreased apoptosis are thought to be important mechanisms for tumor progression, including malignant glioma. Because recent studies have demonstrated that EPO and its receptor (EPOR) are expressed in several tumors and can promote tumor growth, in the present study, we investigated EPO and EPOR expression…

AdultMalemedicine.medical_treatmentBlotting WesternErythropoietin receptor03 medical and health sciences0302 clinical medicineGliomaCell Line TumormedicineReceptors ErythropoietinAnimalsHumansErythropoietinAgedPlatelet Endothelial Cell Adhesion Moleculebusiness.industryBrain NeoplasmsGliomaMiddle Agedmedicine.diseaseImmunohistochemistryRats Inbred F344Recombinant ProteinsErythropoietin receptorTumor BurdenPlatelet Endothelial Cell Adhesion Molecule-1Disease Models AnimalCytokineKi-67 AntigenApoptosisErythropoietinTumor progressionErythropoietin; Erythropoietin receptor; Glioma030220 oncology & carcinogenesisCancer researchErythropoiesisSurgeryFemaleNeurology (clinical)business030217 neurology & neurosurgeryNeoplasm Transplantationmedicine.drugErythropoietin Erythropoietin receptor Glioma
researchProduct

Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transp…

1999

We have determined the effect of delayed addition of G-CSF after chemotherapy on PBPC mobilization in a group of 30 patients with high risk breast cancer (HRBC) undergoing standard chemotherapy followed by high-dose chemotherapy (HDCT) and autologous SCT. Patients received FAC chemotherapy every 21 days followed by G-CSF at doses of 5 microg/kg/day starting on day +15 (groups 1 and 2) or +8 (group 3) after chemotherapy. PBPC collections were performed daily starting after 4 doses of G-CSF and continued until more than 2.5 x 10(6) CD34+ cells had been collected. In group 1, steady-state BM progenitors were also harvested and used for SCT. Groups 2 and 3 received PBPC only. The median number …

AdultRiskmedicine.medical_specialtyAdolescentPlatelet Engraftmentmedicine.medical_treatmentCD34UrologyBreast NeoplasmsTransplantation AutologousBreast cancerAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansMedicineProgenitor cellTransplantationChemotherapybusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseHematopoietic Stem Cell MobilizationSurgeryGranulocyte colony-stimulating factorTransplantationFemaleStem cellbusinessBone Marrow Transplantation
researchProduct

Evaluation of the antiproliferative, proapoptotic, and antiangiogenic effects of a double-stranded RNA mimic complexed with polycations in an experim…

2015

Objective To assess the antiproliferative, proapoptotic, and antiangiogenic effects of the double-stranded RNA mimic polyinosine-polycytidylic acid (pIC) complexed with polyethylenimine [pIC PEI ] in xenografted human leiomyomas. Design Heterologous leiomyoma mouse model. Setting University-affiliated infertility center. Animal(s) Ovariectomized and hormone-replaced nude mice (n = 16) who received human leiomyoma fragment transplantation. Intervention(s) Leiomyoma fragments placed in the peritoneum of 5-week-old nude female mice and treated with the vehicle (n = 8) or 0.6 mg/kg [pIC PEI ] (n = 8) for 4 weeks. Main Outcome Measure(s) The size of the leiomyoma implants, and cellular prolifera…

AdultTime FactorsAngiogenesisOvariectomyHeterologousMice NudeAngiogenesis InhibitorsApoptosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePeritoneummedicineTumor Cells CulturedAnimalsHumansPolyethyleneimineCell ProliferationPolyethylenimine030219 obstetrics & reproductive medicineLeiomyomaNeovascularization PathologicCell growthbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysTumor BurdenTransplantationPlatelet Endothelial Cell Adhesion Molecule-1Disease Models AnimalLeiomyomamedicine.anatomical_structureKi-67 AntigenPoly I-CReproductive MedicinechemistryApoptosis030220 oncology & carcinogenesisImmunologyUterine NeoplasmsCancer researchFemalebusinessFertility and sterility
researchProduct